IBRX 10 Year Annualized Return and Average Annual Return

The IBRX 10 year annualized return is 2.45% with dividends reinvested through 07/17/2026. Investors often use annualized return to compare long-term performance because it shows the average yearly compounded return over a full period rather than just the headline total gain.

This page shows IBRX average annual return, total return, start and end dates, and the growth of a hypothetical $10,000 investment with dividends reinvested.

Quick links: Annualized Return Table  |  Performance Chart  |  FAQ
IBRX Average Annual Return Chart 10 Years
Growth of $10,000.00
Without Dividends Reinvested Into IBRX

Also see:
• IBRX stock yearly return 2016
• IBRX stock yearly return 2017
• IBRX stock yearly return 2018
• IBRX stock yearly return 2019
• IBRX stock yearly return 2020
• IBRX stock yearly return 2021
• IBRX stock yearly return 2022
• IBRX stock yearly return 2023
• IBRX stock yearly return 2024
• IBRX stock yearly return 2025
• IBRX YTD return
Average Annual Return Benchmarks
Compare IBRX average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
IBRX Share Performance
IBRX Average Annual Return Table 10 Years
Start date: 07/19/2016
End date: 07/17/2026
Start price/share: $6.03
End price/share: $7.68
Dividends collected/share: $0.00
Total return: 27.36%
IBRX Average Annual Return: 2.45%
Starting investment: $10,000.00
Ending investment: $12,738.54
Years: 10.00


IBRX average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
About ImmunityBio Inc
ImmunityBio, Inc. is a clinical-stage biotechnology company developing therapies and vaccines to enhance the immune system against cancers and infectious diseases. It uses proprietary platforms to activate both the innate and adaptive immune systems, targeting cancer and pathogens. These platforms include antibody-cytokine fusion proteins, DNA, RNA, and recombinant protein vaccines, and cell therapies. Its lead product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein designed to boost immune response. ImmunityBio aims to orchestrate a comprehensive immune attack on cancer and infectious diseases through its innovative therapies. The IBRX average annual return 10 years is shown above.

The Average Annual Return on the IBRX average annual return 10 years page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether IBRX average annual return 10 years or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the IBRX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
IBRX Current Stock Quote
Quotes delayed 20 minutes

Email EnvelopeFree IBRX Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
Featured Slideshows
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!
Video: Don't Forget Dividends in Average Annual Return!
Average Annual Return Peers
ImmunityBio (IBRX) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

ICCC Average Annual Return
ICLR Average Annual Return
ICUI Average Annual Return
IDXG Average Annual Return
IDXX Average Annual Return
IDYA Average Annual Return
IKT Average Annual Return
ILMN Average Annual Return
IMA Average Annual Return
IMDX Average Annual Return
More Healthcare companies »
What has the average annual return been for IBRX over the past ten years?
✔️Accepted answer: The ten year IBRX average annual return has been 2.45%.

What start date was used in your IBRX average annual return calculation?
✔️Accepted answer: The start date was 07/19/2016.

What end date was used in your IBRX average annual return calculation?
✔️Accepted answer: The end date was 07/17/2026.

If I had invested $10,000 into IBRX ten years ago, how much would I have today?
✔️Accepted answer: Today, as of 07/17/2026, you would have $12,738.54.

What does that work out to on a total return basis?
✔️Accepted answer: The IBRX ten year total return ending 07/17/2026 works out to 27.36%.


Also see:
• IBRX stock yearly return 2016
• IBRX stock yearly return 2017
• IBRX stock yearly return 2018
• IBRX stock yearly return 2019
• IBRX stock yearly return 2020
• IBRX stock yearly return 2021
• IBRX stock yearly return 2022
• IBRX stock yearly return 2023
• IBRX stock yearly return 2024
• IBRX stock yearly return 2025
• IBRX YTD return
 

IBRX 10 Year Annualized Return & Average Annual Return | www.AverageAnnualReturn.com | Copyright © 2021 - 2026, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.